Market/Novel Tech

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced preliminary safety and efficacy data of a Phase 1/2 study of “OCU400”,… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced preliminary safety and efficacy data of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP)

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the completion of the enrollment of a Phase 2 clinical… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the completion of enrollment in a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the acquisition of rights to two preclinical-stage AAV-based gene… Read More »Opus Genetics Inc., has announced the acquisition of rights to two preclinical-stage for inherited retinal diseases (IRDs) from Iveric Bio (NASDAQ: ISEE)

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) has announced that the U.S. Food and Drug Administration (FDA) has approved pegcetacoplan injection (labelled “SYFOVRE”), for the treatment of… Read More »Apellis Pharmaceuticals announce the approval of pegcetacoplan injection for the treatment of geographic atrophy (GA).

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced the publication of updated efficacy results from a pooled analysis of… Read More »GenSight Biologics announces a pooled presentation of LUMEVOQ versus natural history in ND4-LHON.

A French bioelectronics company “Pixium Vision SA” (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), based in Paris, has announced the completion of implantations of an… Read More »Pixium SA has announced the completion of implantations of the “PRIMAvera” trial with the implantation of a bionic artificial retina.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the FDA clearance of its Investigational New Drug (IND)… Read More »Opus Genetics Inc., has announced an IND application for “OPGx-001” for the treatment of LCA5 retinal disease

IVERIC bio, Inc., (NASDAQ: ISEE), based in Parsippany New Jersey, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for… Read More »Avacincaptad pegol (ACP, “Zimura”) for geographic atrophy (IVERIC bio, Inc., NASDAQ: ISEE)) has announced a Breakthrough Therapy Designation from the FDA

Genentech (Roche) has announced a voluntarily recall of the “Susvimo” (ranibizumab injection) ocular implant for wet AMD, citing a manufacturing problem with the device. The… Read More »Genentech (Roche) has announced a voluntarily manufacturing recall for their implant (Port Delivery System with ranibizumab, “Susvimo”) to treat neovascular age-related macular degeneration (nAMD)

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported the completion of enrollment for a Phase 2 study for Stargardt disease.  The study… Read More »Nanoscope Therapeutics Inc., have announced the completion of enrolment for Phase 2 Stargardt disease study with optogenetic gene therapy